VITAERIS INC
Summary
Vitaeris is a clinical-stage biotechnology company focused on the phase III development of clazakizumab, an anti-interleukin-6 (IL-6) monoclonal antibody (MAB), for the potential treatment of chronic active antibody-mediated rejection.
Deals Overview
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.
Senior Management
Kevin Chow
President and CEO
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers